2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Sarcoma
2
Other solid neoplasm
2
Gastrointestinal
2
NET
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Colorectal Neoplasms
105
Carcinoma, Hepatocellular
34
Neoplasm Metastasis
19
Neoplasms
17
Gastrointestinal Stromal Tumors
17
Colonic Neoplasms
14
Rectal Neoplasms
12
Liver Neoplasms
8
Glioblastoma
7
Sarcoma
6
Stomach Neoplasms
5
Sarcoma, Ewing
5
Ovarian Neoplasms
5
Osteosarcoma
5
Melanoma
5
Cholangiocarcinoma
5
Adenocarcinoma
5
Pancreatic Neoplasms
4
Esophageal Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Non-Small-Cell Lung
4
Small Cell Lung Carcinoma
3
Rhabdomyosarcoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Leukemia, Myeloid, Acute
3
Colorectal Cancer Metastatic
3
Carcinoma, Transitional Cell
3
Carcinoma
3
Advanced Colorectal Cancer
3
Thyroid Neoplasms
2
Interventions
Cisplatin
57
Pemetrexed
46
pembrolizumab
18
Nivolumab
15
Carboplatin
15
Gemcitabine
14
Cyclophosphamide
13
Radiotherapy
10
Drug Therapy
9
atezolizumab
8
Platinum
7
Ipilimumab
7
Doxorubicin
7
durvalumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
tremelimumab
5
sodium thiosulfate
5
Vinorelbine
5
Radiotherapy, Intensity-Modulated
5
Interleukin-2
5
Chemotherapy, Adjuvant
5
Cerebral Decortication
5
sargramostim
4
fludarabine
4
defactinib
4
aldesleukin
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
cediranib
3
Photochemotherapy
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
regorafenib
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled